Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability

Biotechnology and Bioengineering

Volumn 108, Issue 11, 2011, Pages 2634-2644

  Conley, Greg P ^a   Viswanathan, Malini ^a   Hou, Ying ^b   Rank, Doug L ^a   Lindberg, Allison P ^a   Cramer, Steve M ^b   Ladner, Robert C ^a   Nixon, Andrew E ^a   Chen, Jie ^a  

^a Dyax Corp   (United States)

^b RPI   (United States)

Author keywords

Aggregation; Monoclonal antibody; Non Protein A purification process; Site mutation

Indexed keywords

AMINO ACID SEQUENCE; ANTIBODY DRUGS; DEGREE OF SPECIFICITY; DRUG MOLECULES; GENERIC PROCESS; IN-PROCESS; MANUFACTURABILITY; NON-PROTEIN A PURIFICATION PROCESS; PHAGE DISPLAY LIBRARIES; PLATFORM PROCESS; PROCESS DEVELOPMENT; PROTEIN A; PROTEIN ENGINEERING; PURIFICATION PROCESS; QUALITY BY DESIGNS; SITE MUTATION;

AGGLOMERATION; AMINO ACIDS; BIOCHEMICAL ENGINEERING; GENETIC ENGINEERING; MONOCLONAL ANTIBODIES; PROTEINS; PURIFICATION;

OPTIMIZATION;

AMINO ACID; HUMAN MONOCLONAL ANTIBODY X; MONOCLONAL ANTIBODY; PROTEIN A; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; DRUG MANUFACTURE; EVALUATION; HYDROPHOBICITY; PHAGE DISPLAY; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROTEIN ENGINEERING; PROTEIN PURIFICATION;

AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; PROTEIN DENATURATION; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 80053053963     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23220     Document Type: Article

References (36)

1. Arunakumari A. 2009. Implementing cost reduction strategies for HumAb manufacturing processes. BioPharm Int 7(1): 48-54.
2. Arunakumari A, Wang J, Ferreira G. 2007. Alternatives to Protein A: Improved downstream process design for human monoclonal antibody production. BioPharm Int 20(2): 36-40.
3. Chaplin M. 2010. Hofmeister Series, Water Structure and Science. .
4. Chen J, Tetrault J, Ley A. 2008. Comparison of standard and new generation hydrophobic interaction chromatography resins in the monoclonal antibody purification process. J Chromatogr A 1177(2): 272-281.
5. Chirino AJ, Mire-Sluis A. 2004. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 22(11): 1383-1391.
6. Chou DK, Krishnamurthy R, Randolph TW, Carpenter JF, Manning MC. 2005. Effects of Tween 20 and Tween 80 on the stability of Albutropin during agitation. J Pharm Sci 94(6): 1368-1381.
7. Chung WK, Hou Y, Freed A, Holstein M, Makhatadze GI, Cramer SM. 2009. Investigation of protein binding affinity and preferred orientations in ion exchange systems using a homologous protein library. Biotechnol Bioeng 102(3): 869-881.
8. Chung WK, Hou Y, Holstein M, Freed A, Makhatadze GI, Cramer SM. 2010. Investigation of protein binding affinity in multimodal chromatographic systems using a homologous protein library. J Chromatogr A 1217(2): 191-198.
9. Cowan R, Whittaker R. 1990. Hydrophobicity indices for amino acid residues as determined by HPLC. Pept Res 3: 75-80.
10. Cromwell MEM, Hilario E, Jacobson F. 2006. Protein aggregation and bioprocessing. AAPS J 8(3): E572-E579.
11. Farid SS. 2007. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B 848: 8-18.
12. Farid SS. 2009. Economic drivers and trade-offs in antibody purification processes. BioPharm Int 22(10): 38-42.
13. Food and Drug Administration (FDA). 2006. Guidance for industry: Quality systems approach to pharmaceutical CGMP regulations. .
14. Gagnon P. 1996. Purification tools for monoclonal antibodies. Tucson, AZ: Validated Biosystems Press.
15. Guerrier L, Girot P, Schwartz W, Boschetti E. 2000. New method for the selective capture of antibodies under physiological conditions. Bioseparation 9: 211-221.
16. Heckler C. 2000. PLSPC 4.4. State St. Rochester, NY: Eastman Kodak, Inc.
17. Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W. 2004. Structure-immunogenicity relationship of therapeutic proteins. Pharm Res 21(6): 897-903.
18. Jagschies G, Gronberg A, Bjorkman T, Lacki K, Johansson HJ. 2006. Technical and economical evaluation of downstream processing options for monoclonal antibody (mAb) production. BioPharm Int 19(6): 10-19.
19. Ladiwala A, Rege K, Breneman CM, Cramer SM. 2003. Investigation of mobile phase salt type effects on protein retention and selectivity in cation-exchange systems using quantitative structure retention relationship models. Langmuir 19: 8443.
20. Lain B, Cacciuttolo MA, Zarbis-Papastoitsis G. 2009. Development of a high-capacity Mab capture step based on cation-exchange chromatography. BioProcess Int 7(5): 26-34.
21. Leardi R, Gonzalez AL. 1998. Genetic algorithms applied to feature selection in PLS regression: How and when to use them. Chemometr Intell Lab Syst 41(2): 195-207.
22. Miyazawa S, Jernigan RL. 1985. Estimation of effective interresidue contact energies from protein crystal-structures-Quasi-chemical approximation. Macromolecules 18(3): 534-552.
23. Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, Walus L, Eldredge J, Capili A, Mi S, Graff C, Garber E. 2010. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci 19(5): 954-966.
24. Rathore AS, Winkle H. 2009. Quality by design for biopharmaceuticals. Nat Biotechnol 27(1): 26-34.
25. Reichert JM, Pavlou A. 2004. Monoclonal antibodies market. Nat Rev Drug Discov 3: 383-384.
26. Sakamoto K, Ito Y, Hakaaki H, Soni PB, Mori T, Sugimura K. 2009. Discovery and characterization of a peptide motif that specifically recognizes a non-native conformation of human IgG induced by acidic pH conditions. J Biol Chem 284(15): 9986-9993.
27. Salabat A, Shamshiri L, Sahrakar F. 2005. Thermodynamic and transport properties of aqueous trisodium citrate system at 298.15 K. J Mol Liq 118: 67-70.
28. Schein CH. 1990. Solubility as a function of protein structure and solvent components. Biotechnology 8: 308-317.
29. Shukla AA, Hinckley PJ, Gupta P, Yinges Y, Hubbard B. 2005. Strategies to address aggregation during Protein A chromatography. BioProcess Int 3(5): 36-45.
30. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. 2007. Downstream processing of monoclonal antibodies-application of platform approaches. J Chromatogr B 848: 28-39.
31. Spencer J, Boschetti E, Bengio S. 2003. Replacing protein A sorbents for the large-scale manufacturing of recombinant antibodies: Hydrophobic charge induction chromatography. BioProcess J 2(3): 67-72.
32. Wang W, Wang YJ, Wang DQ. 2008. Duel effects of Tween 80 on protein stability. Int J Pharm 347: 31-38.
33. Wang XL, Das TK, Singh SK, Kumar S. 2009. Potential aggregation prone regions in biotherapeutics. mAbs 1(3): 254-267.
34. Wilce M, Aguilar M, Hearn M. 1995. Physicochemical basis of amino-acid hydrophobicity scales-Evaluation of four new scales of amino-acid hydrophobicity coefficients derived from RP-HPLC of peptides. Anal Chem 67(7): 1210-1219.
35. Yigzaw Y, Piper R, Tran M, Shukla AA. 2006. Exploitation of the adsorptive properties of depth filters for host cell protein removal during monoclonal antibody purification. Biotechnol Prog 22: 288-296.
36. Zabrecky J. 2008. Why do so many biopharmaceuticals fail? BioProcess Int 6(12): 26-34.